cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Eqrx Inc
2 watching
Current Price
$0
$0.01
(0.43%)
logo-eqrx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,110.24M
52-Week High
52-Week High
6.05
52-Week Low
52-Week Low
1.87
Average Volume
Average Volume
2.29M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,110.24M
icon52-Week High6.05
icon52-Week Low1.87
iconAverage Volume2.29M
iconDividend Yield--
iconP/E Ratio--
What does the Eqrx Inc do?
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company s pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Eqrx Inc make?
News & Events about Eqrx Inc.
Globe Newswire
23days ago
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced ...
Globe Newswire
1month ago
Application is based on data from the pivotal Phase 3 GEMSTONE-302 trial assessing sugemalimab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancerAcceptance of the marketing authorization application (MAA) is EQRxs second from the United Kingdoms ...
Globe Newswire
1month ago
Submission is EQRxs first to European Medicines AgencyApplication is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: ...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the ...
Globe Newswire
3 months ago
CAMBRIDGE, Mass., Oct. 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced it will host a conference call and webcast on Thursday, November ...
Frequently Asked Questions
Frequently Asked Questions
What is Eqrx Inc share price today?
plus_minus_icon
Can Indians buy Eqrx Inc shares?
plus_minus_icon
How can I buy Eqrx Inc shares from India?
plus_minus_icon
Can Fractional shares of Eqrx Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Eqrx Inc stocks?
plus_minus_icon
What is today’s traded volume of Eqrx Inc?
plus_minus_icon
What is today’s market capitalisation of Eqrx Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Eqrx Inc?
plus_minus_icon
What percentage is Eqrx Inc down from its 52-Week High?
plus_minus_icon
What percentage is Eqrx Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.01
(0.43%)
logo-eqrx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00